Halozyme Therapeutics Inc (HALO)
Receivables turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 1,015,320 | 829,253 | 660,116 | 443,310 | 267,594 |
| Receivables | US$ in thousands | — | — | — | — | — |
| Receivables turnover | — | — | — | — | — |
December 31, 2024 calculation
Receivables turnover = Revenue ÷ Receivables
= $1,015,320K ÷ $—K
= —
Based on the provided data, the receivables turnover for Halozyme Therapeutics Inc is unavailable for the years December 31, 2020 to December 31, 2024. The receivables turnover ratio indicates the efficiency with which a company is able to collect payment from its customers.
Since the receivables turnover values are not provided, we are unable to assess how quickly the company is converting its accounts receivable into cash during the specified years. A higher receivables turnover ratio is generally preferred as it signifies a shorter time taken to collect outstanding payments, highlighting better liquidity and operational efficiency. On the other hand, a lower ratio could indicate potential issues with collecting payments promptly or effectively managing credit terms.
In the absence of specific data, we are unable to provide an in-depth analysis of changes or trends in the receivables turnover for Halozyme Therapeutics Inc over the specified period. It is recommended for the company to monitor this ratio closely as it can provide valuable insights into the effectiveness of its credit and collection policies.
Peer comparison
Dec 31, 2024